We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FFIC:NASDAQFlushing Financial Corporation Analysis

Data as of 2026-09-26 - not real-time

$68.75

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

American Funds Invmt Co of Amer F-3 is priced at $68.75, and its moving averages give no clean directional read — the structure is neutral. The last 30 days have lost 3.2%. Relative strength is 50.5 — neutral — and the MACD signal is bullish. Recent trading has carved out support near $67.24 and resistance around $69.57.
The shares look fair at 26.8 times earnings, though no sector average was available for comparison. The 1.08% dividend yield looks covered by current payout levels.
Risk scores 4 out of 10, which is moderate for this asset class. With 30-day volatility of 10.4%, a beta of 1.04 and a maximum drawdown of 16.3%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Trading above the 200-day average of 65.72
  • MACD momentum is positive
  • RSI at 50.5 is in neutral territory

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Trading above the 200-day average of 65.72
  • MACD momentum is positive
  • P/E ratio of 26.8

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E ratio of 26.8
  • Dividend yield of 1.08%
  • 30-day volatility of 10.4%

Key Metrics & Analysis

Financial Health

P/E Ratio26.8

Technical Analysis

TrendNeutral
RSI50.5
Support$67.24
Resistance$69.57
MA 20$68.61
MA 50$68.82
MA 200$65.72
MACDBullish
VolumeStable
Fear & Greed Index94.88

Valuation

GradeFair
TypeBlend
Dividend Yield1.08%

Risk Assessment

Beta1.04
Volatility10.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.